CD19 and acute lymphoblastic leukemia: CAR-T cell therapy, as a paradigm-shifting modality, has achieved unprecedented success in hematological malignancies by redirecting αβ T cells to eradicate CD19+ B-cell malignancies, such as acute lymphoblastic leukemia(ALL) and adult high-grade B-cell lymphoma [1].